A Phase 1, Open-label, Fixed-sequence, Crossover Study to Investigate the Effect of Coadministration of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-16673 in Healthy Participants
Latest Information Update: 22 Apr 2025
At a glance
- Drugs BGB-16673 (Primary) ; Itraconazole (Primary) ; Phenytoin (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Pharmacokinetics
- Sponsors BeiGene
- 17 Apr 2025 Status changed from not yet recruiting to recruiting.
- 07 Apr 2025 New trial record